SCHEMBL6330757

SCHEMBL6330757

COc1cc2c(c3c1cc(CO)n3Cc1ccccc1F)CCC2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 5/20 0.48
PDE4B Q07343 1/20 0.41
FABP3 P05413 1/20 0.39
FABP4 P15090 2/20 0.39
P2RX7 Q99572 1/20 0.39
KMT2A Q03164 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPK1 P28482 1/20 0.37
KDM4E B2RXH2 1/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
MEN1 O00255 3/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6339344 0.86 PLA2G2A (0.46) PLA2G2AFABP4P2RX7
SCHEMBL6334760 0.84 PLA2G2A (0.47) PLA2G2APDE4BFABP4KMT2ASMN1; SMN2
SCHEMBL6339378 0.84 PLA2G2A (0.46) PLA2G2APDE4BFABP3FABP4
SCHEMBL6333110 0.83 PLA2G2A (0.49) PLA2G2AFABP3FABP4KMT2ABCHE
SCHEMBL6333107 0.78 PLA2G2A (0.45) PLA2G2AFABP4KDM4E
SCHEMBL6330547 0.75 PLA2G2A (0.67) PLA2G2AFABP3FABP4KMT2AALDH1A1
SCHEMBL6332702 0.74 PLA2G2A (0.39) PLA2G2AFABP4KMT2AALDH1A1KDM4E
SCHEMBL6335034 0.74 PLA2G2A (0.48) PLA2G2APDE4BFABP4P2RX7
SCHEMBL6337283 0.71 PLA2G2A (0.48) PLA2G2AFABP4P2RX7SMN1; SMN2ALDH1A1
SCHEMBL6333100 0.70 PLA2G2A (0.48) PLA2G2AFABP4P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6974831-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2005-12-13 US disclosed
US-20040077704-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077704-A1 Novel spla2 inhibitors PLAAT2, PLA2G12A, PLA2G4A PLA2G2A 19/4885PDE4B 2353/4885FABP3 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.